Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.

Journal of Virology
Claire Bertaux, Tatjana Dragic

Abstract

The CD81 tetraspanin was first identified as a hepatitis C virus (HCV) receptor by its ability to bind the soluble ectodomain of envelope glycoprotein E2 (sE2). More recently, it has been suggested that CD81 is necessary but not sufficient for HCV entry into target cells. Here we present further evidence that putative human hepatocyte-specific factors act in concert with CD81 to mediate sE2 binding and HCV pseudoparticle (HCVpp) entry. Moreover, we show that CD81-mediated HCVpp entry entails E2 binding to residues in the large extracellular loop as well as molecular events mediated by the transmembrane and intracellular domains of CD81. The concept that CD81 receptor function progresses in stages is further supported by our finding that anti-CD81 monoclonal antibodies inhibit HCVpp entry by different mechanisms. The half-life of CD81-HCVpp binding was determined to be approximately 17 min, and we propose that binding is followed by CD81 oligomerization, partitioning into cholesterol-rich membrane domains, or other, lateral protein-protein interactions. This results in the formation of a receptor-virus complex that undergoes endocytosis and pH-dependent membrane fusion.

References

Jan 26, 1995·Biochemical and Biophysical Research Communications·N KatoK Shimotohno
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·D RosaS Abrignani
Oct 30, 1998·Science·P PileriS Abrignani
Jul 10, 1999·Journal of Virology·M FlintJ A McKeating
Apr 25, 2000·Journal of Virology·R PetraccaG Grandi
Aug 16, 2001·The Journal of Biological Chemistry·C S StippM E Hemler
Sep 11, 2001·The Journal of Infectious Diseases·J BoisvertH B Greenberg
Jan 5, 2002·The Journal of Cell Biology·M E Hemler
Apr 18, 2002·FEBS Letters·Stéphanie CharrinEric Rubinstein
Feb 11, 2003·Trends in Biochemical Sciences·Christopher S StippMartin E Hemler
Mar 5, 2003·The Journal of Experimental Medicine·Birke BartoschFrançois-Loïc Cosset
Apr 24, 2003·The Biochemical Journal·Stéphanie CharrinEric Rubinstein
May 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Mayla HsuJane A McKeating
Aug 13, 2003·The Journal of Biological Chemistry·Birke BartoschFrançois-Loïc Cosset
Aug 26, 2003·European Journal of Immunology·Stéphanie CharrinEric Rubinstein
Dec 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anu CherukuriSusan K Pierce
Jan 15, 2004·Journal of Virology·Jie ZhangJane A McKeating
Feb 18, 2004·The Journal of Biological Chemistry·Krista L ClarkScott C Todd
May 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Emmanuel G CormierTatjana Dragic
May 27, 2004·The Journal of Biological Chemistry·Anu CherukuriSusan K Pierce
Aug 25, 2004·Biology of the Cell·Cécile Voisset, Jean Dubuisson
Jan 22, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Dimitri LavilletteFrançois-Loïc Cosset
Jun 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jin ZhongFrancis V Chisari
Jun 11, 2005·Science·Brett D LindenbachCharles M Rice

❮ Previous
Next ❯

Citations

Sep 2, 2008·Nature Reviews. Drug Discovery·Martin E Hemler
Jul 9, 2011·The Journal of Biological Chemistry·Nishi R SharmaGregory B Melikyan
Oct 26, 2012·The Journal of Biological Chemistry·Zhe LiuJing-hsiung James Ou
Sep 1, 2006·Journal of Virology·Mike FlintJane A McKeating
Jun 29, 2012·Journal of Virology·Sundaresan RajeshMichael Overduin
May 25, 2007·Journal of Virology·Timothy L TellinghuisenCharles M Rice
Sep 17, 2010·Journal of Virology·Maria L MichtaMatthew J Evans
Feb 1, 2008·Journal of Virology·Laurent MeertensTatjana Dragic
Feb 10, 2012·Journal of Virology·Michelle J FarquharJane A McKeating
Nov 10, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Noha HassunaLynda J Partridge
May 28, 2013·Clinical & Developmental Immunology·Shih-Hsien HsuShen-Nien Wang
Dec 20, 2014·Cell Host & Microbe·Qiang DingAlexander Ploss
Sep 11, 2013·Nature Reviews. Microbiology·Brett D Lindenbach, Charles M Rice
Jul 16, 2008·Clinics in Liver Disease·Zania StamatakiJane A McKeating
Dec 18, 2007·Cellular Microbiology·Jean DubuissonLaurence Cocquerel
Nov 16, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mirjam B ZeiselThomas F Baumert
Dec 18, 2008·Journal of Viral Hepatitis·M J Farquhar, J A McKeating
Nov 7, 2012·Cellular Microbiology·H J HarrisJ A McKeating
Mar 7, 2009·The Journal of General Virology·Michela E Burlone, Agata Budkowska
Sep 13, 2016·ACS Infectious Diseases·Che C ColpittsThomas F Baumert
Aug 11, 2012·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Baila SamreenShah Jahan
Dec 15, 2010·Journal of Hepatology·Mirjam B ZeiselThomas F Baumert
May 7, 2016·PLoS Pathogens·Satomi YamamotoYoshiharu Matsuura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.